Difference in opioid utilisation between the COVID-19 groups and Controls at referral and at follow-up
| COVID-19 (n=260) | Controls (n=288) | P value | |
| Percentage of patients on opioid at referral (95% CI) (n) | 0.005 | ||
| Weak opioid | 38.6% (32% to 44%)(98/254) | 49.8% (44% to 56%)(143/287) | |
| Strong opioid | 2.0% (0% to 4%) (5/254) | 2.8% (1% to 5%)(8/287) | |
| Any opioid | 40.6% (35% to 47%)(103/254) | 52.6% (47% to 58%)(151/287) | |
| Percentage of patients on opioid at follow-up (95% CI) (n) | 0.002 | ||
| Weak opioid | 50.8% (45% to 57%)(132/260) | 36.4%(31% to 42%)(99/272) | |
| Strong opioid | 4.2% (2% to 7%)(11/260) | 4.8% (2% to 7%)(13/272) | |
| Any opioid | 55.0% (49% to 61%)(143/260) | 41.2% (35% to 47%)(112/272) |
Table created by the authors.
The denominator for numbers (n) of patients included at each stage reflects data availability for each specific subgroup.